|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:tenofovir_alafenamide
emtricitabine
|
|
gptkbp:approvedBy
|
gptkb:pre-exposure_prophylaxis_(PrEP)
gptkb:FDA
2016
HIV-1 infection
|
|
gptkbp:associatedWith
|
gptkb:Truvada
|
|
gptkbp:ATCCode
|
J05AR17
|
|
gptkbp:brand
|
emtricitabine/tenofovir alafenamide
|
|
gptkbp:contraindication
|
severe renal impairment
hypersensitivity to components
|
|
gptkbp:cost
|
high
|
|
gptkbp:drugClass
|
antiretroviral therapy
combination drug
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:genericAvailable
|
no
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Descovy
|
|
gptkbp:indication
|
pre-exposure prophylaxis (PrEP) to reduce risk of HIV-1 infection
treatment of HIV-1 infection in combination with other antiretrovirals
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Gilead_Sciences
|
|
gptkbp:marketedIn
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
nucleoside reverse transcriptase inhibitor (NRTI)
nucleotide reverse transcriptase inhibitor (NtRTI)
|
|
gptkbp:notRecommendedFor
|
PrEP in individuals at risk from receptive vaginal sex
|
|
gptkbp:patent
|
gptkb:Gilead_Sciences
|
|
gptkbp:pregnancyCategory
|
B
|
|
gptkbp:prescribes
|
adults
adolescents weighing at least 35 kg
|
|
gptkbp:prescriptionRequired
|
yes
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
abdominal pain
fatigue
headache
|
|
gptkbp:storage
|
store below 30°C (86°F)
|
|
gptkbp:bfsParent
|
gptkb:PrEP
gptkb:Gilead_Sciences,_Inc.
|
|
gptkbp:bfsLayer
|
6
|